Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 1, 2006, Pages 67-78

  Ruud, E ^a   Holmstrom H ^a   Brosstad, F ^a   Wesenberg, F ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Congenital heart defects; Homocysteine; Thrombophilia

Indexed keywords

BLOOD CLOTTING INHIBITOR; HOMOCYSTEINE; LIPOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER REGRESSION; CHILD; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; HEART CATHETERIZATION; HOMOCYSTINURIA; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM;

EID: 32344440829     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510500453003     Document Type: Article

References (33)

1. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7.
2. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-81.
3. Andrew M, Monagle PT, Brooker L. Thromboembolic complications during infancy and childhood. Hamilton, London: B.C. Decker Inc.; 2000.
4. Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer: a prospective study. Med Pediatr Oncol 2002;38:405-10.
5. Chalmers E. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2005. In press.
6. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001;161:2433-9.
7. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'asparaginase-induced antithrombin III deficiency. Blood 1994;83:386-91.
8. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-45.
9. Reller MD. Congenital heart disease: current indications for antithrombotic therapy in pediatric patients. Curr Cardiol Rep 2001;3:90-5.
10. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86:464-74.
11. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukaemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-72.
12. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-75.
13. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202.
14. Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 2001;39:725-33.
15. Vilaseca MA, Moyano D, Artuch R, Ferrer I, Pineda M, Cardo E, et al. Selective screening for hyperhomocysteinemia in pediatric patients. Clin Chem 1998;44:662-4.
16. Coppola A, Davi G, De Stefano, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000;26:243-54.
17. Osganian SK, Stampfer MJ, Spiegelman D, Rimm E, Cutler JA, Feldman HA, et al. Distribution of and factors associated with serum homocysteine levels in children: Child and adolescent trial for cardiovascular health. JAMA 1999;281:1189-96.
18. De Laet C, Wautrecht JC, Brasseur D, Dramaix M, Boeynaems JM, Decuyper J, et al. Plasma homocysteine concentration in a Belgian school-age population. Am J Clin Nutr 1999;69:968-72.
19. Vilaseca MA, Moyano D, Ferrer I, Artuch R. Total homocysteine in pediatric patients. Clin Chem 1997;43:690-2.
20. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
21. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharamcogenetics and neurotoxicity in children with leukaemia. J Clin Oncol 2003;21:3084-91.
22. Cappuccio FP, Bell R, Perry IJ, Gilg J, Ueland PM, Refsum H, et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002;164:95-102.
23. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002;13:423-31.
24. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
25. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999;81:739-44.
26. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000;26:263-79.
27. Steinmetz J, Choukalfe A, Visvikis S, Henny J, Slest G. Biological factors affecting concentrations of serum LpAI lipoprotein particles in serum and determination of reference limits. Clin Chem 1990;36:806-12.
28. Nowak-Gottl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999;100:743-8.
29. Nowak-Gottl U, Debus O, Findeisen M, Kassenbohmer R, Koch HG, Pollmann H, et al. Lipoprotein(a): its role in childhood thromboembolism. Pediatrics 1997;99:E11.
30. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-8.
31. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001;98:2980-7.
32. Constans J, Wendling G, Peuchant E, Camilleri G, Conri C. Lipoprotein(a) in 505 hospitalized patients with various pathological states: correlations with cardiovascular diseases and therapies. Int Angiol 1996;15:1-5.
33. Nakajima K, Hata Y. Intraindividual variations in lipoprotein (a) levels and factors related to these changes. J Atheroscler Thromb 1996;2:96-106.